Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


Form 8-K

 


CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported):

March 16, 2006

 


PDL BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

 


 

Delaware   000-19756   94-3023969

(State or other jurisdiction

of incorporation)

  (Commission File No.)  

(I.R.S. Employer

Identification No.)

34801 Campus Drive

Fremont, California 94555

(Address of principal executive offices)

Registrant’s telephone number, including area code:

(510) 574-1400

 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



Item 1.01. Entry into a Material Definitive Agreement.

The Compensation Committee of the Board of Directors of PDL BioPharma, Inc. (the “Company”) approved the following bonuses for fiscal year 2005 and the following annual salaries for fiscal year 2006, beginning as of January 1, 2006, for the Company’s “named executive officers” (as defined in Item 402(a)(3) of Regulation S-K promulgated by the U.S. Securities and Exchange Commission):

 

Name

  

Title

  

Annual Salary for Fiscal Year 2006,

Beginning as of January 1, 2006

   Bonus for
Service in Fiscal
Year 2005

Mark McDade

   Chief Executive Officer    $600,000 ($54,000 increase from $546,000 annual salary for fiscal year 2005)*    $ 400,000

Steve Benner

  

Senior Vice President

and Chief Medical Officer

   $383,000 ($6,749 increase from $376,251 annual salary for fiscal year 2005)    $ 125,000

Rich Murray

  

Senior Vice President

and Chief Scientific

and Technical Officer

   $375,000 ($25,000 increase from $350,000 annual salary for fiscal year 2005)    $ 140,000

Jaisim Shah

  

Senior Vice President,

Marketing and

Business Affairs

   $287,000 ($6,185 increase from $280,815 annual salary for fiscal year 2005)    $ 100,000

Laurie Torres

  

Vice President,

Human Resources and

Corporate Services

   $250,000 ($14,724 increase from $235,276 annual salary for fiscal year 2005)    $ 95,000

* Notwithstanding the foregoing, the salary increase for Mr. McDade was approved by the Company’s Board of Directors upon the recommendation of the Compensation Committee.

The approval of the above-listed actions by the Company’s Board of Directors and Compensation Committee, as applicable, became effective as of March 16, 2006.

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 17, 2006

 

PDL BIOPHARMA, INC.
By:  

/s/ Mark McDade

  Mark McDade
  Chief Executive Officer

 

3